Adrian R. Krainer
Co-Founder & Independent DirectorDr. Adrian R. Krainer, Ph.D., serves as Member of Scientific Advisory Board of Ceptur Therapeutics, Inc. since January 2022. He serves as a Member of Scientific Advisory Board at Envisagenics, Inc. He had been the Member of Scientific Advisory Board at Stoke Therapeutics, Inc. since 2020 until 2023. He serves as Independent Director of Stoke Therapeutics, Inc. since June 2014. He is Co-Founder of Stoke Therapeutics, Inc. He served as Member of Scientific Advisory Board at Skyhawk Therapeutics, Inc. until September 2025. He is the St. Giles Professor at Cold Spring Harbor Laboratory, where he has been since 1986 and where his work led directly to the invention and development of SPINRAZA. He is a Deputy Director of Research of the CSHL Cancer Center. He is a world expert on the role of RNA splicing proteins in cancer, neurological and rare diseases. He has published widely on RNA splicing in spinal muscular atrophy (SMA). He was elected to the American Academy of Arts and Sciences for his work in this field and serves as a Board Member and advisor for multiple companies and organizations. He is the recipient of the Life Sciences Breakthrough Prize, the RNA Society’s Lifetime Achievement Award, the Reemtsma Foundation International Prize in Translational Neuroscience, the Speiser Award in Pharmaceutical Sciences and the Ross Prize in Molecular Medicine, amongst others. He previously served as the President of the RNA Society and is a Member of the National Academy of Sciences, the National Academy of Medicine, the National Academy of Inventors and the American Academy of Arts & Sciences. He received his PhD in Biochemistry from Harvard University. He holds a B.A. in Biochemistry from Columbia University.
公司職務
- 公司名稱Stoke Therapeutics, Inc.股票代碼STOK職務Co-Founder & Independent Director
